Abgenics Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 06-12-2024
- Paid Up Capital ₹ 0.10 M
as on 06-12-2024
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 130.60%
(FY 2020)
- Profit 45.05%
(FY 2020)
- Ebitda 43.50%
(FY 2020)
- Net Worth -7.93%
(FY 2020)
- Total Assets 28.94%
(FY 2020)
About Abgenics Life Sciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjiban Banerjee, Gaurav Nahar, and Sunil Nahar serve as directors at the Company.
- CIN/LLPIN
U73100PN2010PTC136454
- Company No.
136454
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2010
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Abgenics Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjiban Banerjee  | Director | 01-Jun-2010 | Current |
| Gaurav Nahar | Additional Director | 13-Sep-2022 | Current |
| Sunil Nahar | Director | 01-Jun-2010 | Current |
Financial Performance of Abgenics Life Sciences.
Abgenics Life Sciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 130.6% increase. The company also saw a substantial improvement in profitability, with a 45.05% increase in profit. The company's net worth dipped by a decrease of 7.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abgenics Life Sciences?
In 2018, Abgenics Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Defiant Renewables Private LimitedActive 8 years 8 monthsGaurav Nahar and Sunil Nahar are mutual person
Defiant Energy Private LimitedActive 24 years 8 monthsGaurav Nahar and Sunil Nahar are mutual person
- Saiseva Biotech Private LimitedActive 14 years 11 days
Gaurav Nahar and Sunil Nahar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Abgenics Life Sciences?
Unlock and access historical data on people associated with Abgenics Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abgenics Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abgenics Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
